Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders

Patent metadata

Field	Value
Publication number	US-11827633-B2
Application number	US-202117409513-A
Country	US
Kind code	B2
Filing date	Aug 23, 2021
Priority date	Nov 7, 2016
Publication date	Nov 28, 2023
Grant date	Nov 28, 2023

Abstract

The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles of the formula (I), in which A, E, G, R1 to R6 and R10 are as defined in the claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which a regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis. The invention furthermore relates to processes for the synthesis of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.

First claim

The invention claimed is:

1. A method of stimulating chondrogenesis or cartilage formation in a subject in need thereof, comprising administering an effective amount of the compound of formula I:

wherein:
A is selected from the group consisting of phenyl and a monocyclic or bicyclic, 5-membered to 10-membered, aromatic heterocyclic group,
wherein the aromatic heterocyclic group comprises 1 or 2 identical or different hetero ring members selected from the group consisting of N, N(R 20 ), O and S, and is bonded via a ring carbon atom, and
wherein the phenyl and the aromatic heterocyclic group are unsubstituted or substituted on ring carbon atoms by one or more identical or different substituents R 21 ;

E is a direct bond or a chain consisting of 1 to 5 chain members of which 0, 1 or 2 chain members are identical or different hetero chain members selected from the group consisting of N(R 25 ), O and S(O) m , and the other chain members are identical or different groups C(R 26 )(R 2 );
G is selected from the group consisting of hydrogen, halogen, (C 1 -C 4 )-alkyl, cyano and R 30 ;
R 1 , R 3 , R 4 and R 6 are independently selected from the group consisting of hydrogen, halogen and (C 1 -C 4 )-alkyl;
R 2 is selected from the group consisting of hydrogen, halogen, (C 1 -C 4 )-alkyl and (C 1 -C 4 )-alkyl-O—C(O)—;
R 5 is selected from the group consisting of hydrogen, halogen, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkyl-O—, cyano, R 7 —O—C(O)— and R 8 —N(R 9 )—C(O)—;
R 7 , R 8 , R 9 , R 20 , R 22 , R 25 , R 31 , R 33 , R 34 and R 40 are independently selected from the group consisting of hydrogen and (C 1 -C 4 )-alkyl;
R 10 is selected from the group consisting of hydrogen, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl and (C 3 -C 7 )-cycloalkyl,
wherein the (C 1 -C 6 )-alkyl group is unsubstituted or substituted by 1 or 2 identical or different substituents selected from the group consisting of (C 3 -C 7 )-cycloalkyl, Het, cyano and (C 1 -C 4 )-alkyl-O—, and
wherein each (C 3 -C 7 )-cycloalkyl group is unsubstituted or substituted by one or more identical or different substituents selected from the group consisting of fluorine and (C 1 -C 4 )-alkyl;

R 21 is selected from the group consisting of halogen, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkyl-O— and cyano,
or two groups R 21 attached to adjacent ring carbon atoms in group A are taken together with the carbon atoms to which they are attached to form a 5-membered to 7-membered mono-unsaturated ring comprising 0, 1 or 2 identical or different hetero ring members selected from the group consisting of N(R 22 ), O and S(O) m , and which is unsubstituted or substituted on ring carbon atoms by one or more identical or different substituents selected from the group consisting of fluorine and (C 1 -C 4 )-alkyl;
R 26 and R 27 are independently selected from the group consisting of hydrogen, fluorine, (C 1 -C 4 )-alkyl and hydroxy, and in one or two groups C(R 26 )(R 27 ), the substituents R 26 and R 27 attached to the same carbon atom are optionally taken together to form oxo;
R 30 is a monocyclic or bicyclic, 3-membered to 10-membered ring, which is saturated or unsaturated and comprises 0, 1, 2 or 3 identical or different hetero ring members selected from the group consisting of N, N(R 31 ), O and S(O) m , and which is unsubstituted or substituted on ring carbon atoms by one or more identical or different substituents R 32 ;
R 32 is selected from the group consisting of halogen, (C 1 -C 4 )-alkyl, hydroxy, oxo, (C 1 -C 4 )-alkyl-O—, cyano, R 33 —N(R 34 )— and Het; and
m is selected from the group consisting of 0, 1 and 2, wherein all numbers m are independent of each other and are identical or different;
wherein Het is a monocyclic, 4-membered to 7-membered, saturated heterocyclic group comprising 1 or 2 identical or different hetero ring members selected from the group consisting of N, N(R 40 ), O and S(O) m , and which is unsubstituted or substituted on ring carbon atoms by one or more identical or different substituents selected from the group consisting of fluorine and (C 1 -C 4 )-alkyl; and
wherein each alkyl group, independently of any other substituents which can be present on an alkyl group, is optionally substituted by one or more fluorine substituents,
provided that the compound of formula I is not 8-phenyl-9H-pyrido[3,4-b]indole,
or a pharmaceutically acceptable salt thereof, to the subject.

2. A method of inducing SOX transcription factors in a subject in need thereof, comprising administering an effective amount of the compound of formula I:

wherein:
A is selected from the group consisting of phenyl and a monocyclic or bicyclic, 5-membered to 10-membered, aromatic heterocyclic group,
wherein the aromatic heterocyclic group comprises 1 or 2 identical or different hetero ring members selected from the group consisting of N, N(R 20 ), O and S, and is bonded via a ring carbon atom, and
wherein the phenyl and the aromatic heterocyclic group are unsubstituted or substituted on ring carbon atoms by one or more identical or different substituents R 21 ;

E is a direct bond or a chain consisting of 1 to 5 chain members of which 0, 1 or 2 chain members are identical or different hetero chain members selected from the group consisting of N(R 25 ), O and S(O) m , and the other chain members are identical or different groups C(R 26 )(R 27 );
G is selected from the group consisting of hydrogen, halogen, (C 1 -C 4 )-alkyl, cyano and R 30 ;
R 1 , R 3 , R 4 and R 6 are independently selected from the group consisting of hydrogen, halogen and (C 1 -C 4 )-alkyl;
R 2 is selected from the group consisting of hydrogen, halogen, (C 1 -C 4 )-alkyl and (C 1 -C 4 )-alkyl-O—C(O)—;
R 5 is selected from the group consisting of hydrogen, halogen, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkyl-O—, cyano, R 7 —O—C(O)— and R 8 —N(R 9 )—C(O)—;
R 7 , R 1 , R 9 , R 20 , R 22 , R 25 , R 31 , R 33 , R 34 and R 40 are independently selected from the group consisting of hydrogen and (C 1 -C 4 )-alkyl;
R 10 is selected from the group consisting of hydrogen, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkynyl and (C 3 -C 7 )-cycloalkyl,
wherein the (C 1 -C 6 )-alkyl group is unsubstituted or substituted by 1 or 2 identical or different substituents selected from the group consisting of (C 3 -C 7 )-cycloalkyl, Het, cyano and (C 1 -C 4 )-alkyl-O—, and
wherein each (C 3 -C 7 )-cycloalkyl group is unsubstituted or substituted by one or more identical or different substituents selected from the group consisting of fluorine and (C 1 -C 4 )-alkyl;

R 21 is selected from the group consisting of halogen, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkyl-O— and cyano,
or two groups R 21 attached to adjacent ring carbon atoms in group A are taken together with the carbon atoms to which they are attached to form a 5-membered to 7-membered mono-unsaturated ring comprising 0, 1 or 2 identical or different hetero ring members selected from the group consisting of N(R 22 ), O and S(O) m , and which is unsubstituted or substituted on ring carbon atoms by one or more identical or different substituents selected from the group consisting of fluorine and (C 1 -C 4 )-alkyl;
R 26 and R 27 are independently selected from the group consisting of hydrogen, fluorine, (C 1 -C 4 )-alkyl and hydroxy, and in one or two groups C(R 26 )(R 27 ), the substituents R 26 and R 27 attached to the same carbon at

Assignees

• Sanofi Sa

Inventors

• Gretzke Dirk
• Ritzeler Olaf
• Heinelt Uwe
• Wehner Volkmar
• Schmidt Friedemann

Classifications

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• A61K31/437

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• C07D519/00

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title

• A61P19/04

  for non-specific disorders of the connective tissue · CPC title